Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ATN-224 analogue; Coprexa; TTM

Latest Information Update: 17 Feb 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Synthetic Biologics
  • Class Heavy metals; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor inhibitors; Chelating agents; Fibroblast growth factor inhibitors; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary fibrosis

Highest Development Phases

  • Suspended Alzheimer's disease; Hepatolenticular degeneration; Huntington's disease; Primary biliary cirrhosis; Pulmonary fibrosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Feb 2012 Adeona Pharmaceuticals is now called Synthetic Biologics
  • 02 Sep 2009 Adeona Pharmaceuticals is seeking partners for further development of Tetrathiomolybdate (http://www.adeonapharma.com/)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top